Overview
Sartorius Stedim Biotech is a life-sciences supplier focused on technologies and services for biopharmaceutical development and manufacturing. Its portfolio includes solutions for cell-line development and media, bioreactors, separation and purification, and the storage and transport of biopharmaceutical products, with single-use technologies among its core offerings.[1][2] The company’s stated mission is to help biopharma customers accelerate drug development and improve manufacturing efficiency, supporting the development of better therapies and more affordable medicine.[3]
Sartorius Stedim Biotech operates internationally, with a presence in around 30 countries and more than 50 locations.[4] For the year ended December 31, 2025, it reported revenue of €2,967.5 million and 10,265 employees.[5][6] [1][2][3][4][5][6][1][2][3][4]
Products & services
Sartorius Stedim Biotech’s product portfolio supports biologics manufacturing across cell lines, cell-culture media and reagents; bioreactors; separation, purification and concentration; storage and transport; and process-modelling and optimization software. Applications include monoclonal antibodies, vaccines, antibody-drug conjugates, and cell and gene therapies. The company offers integrated process solutions, including scalable single-use technologies and solutions for intensified or continuous production.[7][8]
Examples include the **Biostat STR Generation 3** single-use bioreactor, with working volumes from 12.5 to 2,000 L; **Sartopore Evo** sterilizing-grade PES membrane filters, including a 0.8 μm prefilter/0.2 μm final-filter configuration; **Flexsafe** single-use bags for fluid storage, shipping, filtration and transfer; and **Sartoflow Advanced**, a modular benchtop tangential-flow filtration system for ultrafiltration and diafiltration.[9][10][11][12]
Services include process design, plant planning, validation support, bioprocess consulting and engineering, scale-up, process optimization and validation studies for single-use systems and conventional equipment. Sterile single-use products account for “a good three quarters” of sales revenue, with the share varying by product group and region; the cited report does not give a more granular revenue breakdown by individual product or service.[8][13][14][15] [7][8][15][9][10][11][12][13][14]
Geographic presence
In 2025, Sartorius Stedim Biotech generated about 42% of sales in EMEA (€1,241.5 million), 35% in the Americas (€1,053.4 million) and 23% in Asia|Pacific (€672.6 million). North America and Asia are identified as focal areas in its regional growth strategy.[16][17] Country-level sales included €995.7 million in the United States, €255.8 million in Germany, €173.3 million in China, €157.2 million in South Korea and €120.9 million in France.[18]
At year-end 2025, the company reported 7,131 employees in EMEA, 1,724 in the Americas and 1,410 in APAC.[6] The parent company is based in Aubagne, France; its listed group entities span several countries, including France, Germany, Belgium, the United Kingdom and Israel. The company identifies a cell-culture-media facility in Beit HaEmek, Israel, and has also reported manufacturing and R&D expansions in Aubagne and Illkirch, France.[19][20][21][22] [16][17][18][6][19][20][21][22]
Business segments
Sartorius Stedim Biotech reports one operating business segment, **Biopharm**, which accounts for 100% of group sales. Its portfolio serves pharmaceutical and biotechnology companies and contract manufacturers, covering cell lines, culture media and reagents, bioreactors, separation and purification technologies, storage and transport solutions, and process-analysis software. In 2025, Biopharm sales were €2,967.5 million.[23][24][7]
Geography is disclosed as a sales view rather than a separate operating segment. In 2025, sales were approximately 42% EMEA, 35% Americas, and 23% Asia Pacific. The 2026 first-half report also presents regional sales, but does not identify additional business segments.[16][25] [23][24][7][16][25]
Company history
Stedim was founded in Aubagne, France, in 1978 by Bernard Lemaître and Bernard Vallot. In the early 1990s it developed single-use bag systems for biopharmaceutical manufacturing, and in 1994 it became publicly listed on the Paris stock exchange.[26]
On June 29, 2007, Stedim merged with Sartorius’s Biotechnology Division to form Sartorius Stedim Biotech, which was listed on Euronext Paris.[27] The company subsequently expanded its bioprocess and development capabilities through acquisitions including TAP Biosystems in 2013, BioOutsource and Cellca in 2015, and Umetrics in 2017.[28][29][30][31]
From 2021 to 2023, acquisitions of CellGenix, Xell, Albumedix and Polyplus broadened its offerings for cell and gene therapies and other advanced biologics.[32][33][34][35] In 2025, the company completed an expansion at its Aubagne site, adding manufacturing, research and development, and logistics capacity.[22] [26][27][28][29][30][31][32][33][34][35][22]
Sources
- www.sartorius.com[1]
- www.sartorius.com[2]
- www.sartorius.com[3]
- www.sartorius.com[4]
- SARTORIUS STEDIM BIOTECH — Full financial report (2025 Y)
- www.sartorius.com[9]
- shop.sartorius.com[10]
- www.sartorius.com[11]
- www.sartorius.com[12]
- www.sartorius.com[13]
- www.sartorius.com[14]
- www.sartorius.com[21]
- www.sartorius.com[22]
- www.sartorius.com[25]
- www.sartorius.com[26]
- www.sartorius.com[27]
- ir-reports.sartorius.com[28]
- www.sartorius.com[29]
- www.sartorius.com[30]
- www.sartorius.com[31]
- www.sartorius.com[32]
- www.sartorius.com[33]
- www.sartorius.com[34]
- www.sartorius.com[35]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore SARTORIUS STEDIM BIOTECH in Finbar ↗